Clinical trial
A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide)…
NCT00089492 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00089492 |
|---|---|
| Title | A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients |
| Official title | A Phase II Open-label, Randomized, Active-controlled Study Comparing the Efficacy and Safety of Once Daily Enfuvirtide Dosing Versus the Currently Recommended Twice Daily Dosing in HIV-1 Infected Treatment-experienced Patients. |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Collaborators | Trimeris Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Optimized Background ARVs, enfuvirtide [Fuzeon] |
| Enrollment | 64 |
| Start date | Jul 1, 2004 |
| Primary completion | Jun 1, 2006 |
| Completion | Jun 1, 2006 |
| First posted | Aug 6, 2004 |
| Last update posted | Nov 2, 2016 |
| Countries | Canada, Puerto Rico, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: